de Boer A - Search Results

1

Liver blood flow as a major determinant of the clearance of recombinant human tissue-type plasminogen activator.

de Boer A, Kluft C, Kroon JM, Kasper FJ, Schoemaker HC, Pruis J, Breimer DD, Soons PA, Emeis JJ, Cohen AF. de Boer A, et al. Thromb Haemost. 1992 Jan 23;67(1):83-7. Thromb Haemost. 1992. PMID: 1615490

2

Influence of heparin and a low molecular weight heparinoid on specific endogenous and exogenous fibrinolytic factors during rest and exercise.

de Boer A, Kluft C, Dooijewaard G, Kasper FJ, Kroon JM, Breimer DD, Stiekema JC, Cohen AF. de Boer A, et al. Thromb Haemost. 1992 Nov 10;68(5):550-5. Thromb Haemost. 1992. PMID: 1280862 Clinical Trial.

3

Clearance of plasminogen activator--a major determinant of plasma concentration: therapeutic and diagnostic implications.

Cohen AF, Burggraaf K, de Boer A, Kluft C. Cohen AF, et al. Among authors: de boer a. Ann N Y Acad Sci. 1992 Dec 4;667:443-9. doi: 10.1111/j.1749-6632.1992.tb51646.x. Ann N Y Acad Sci. 1992. PMID: 1309067 Review. No abstract available.

4

Pronounced effects of the combination of a new thromboxane antagonist (GR32191) and heparin on bleeding time in man.

de Boer A, Kroon JM, Kroon C, van Vliet A, Schoemaker HC, Breimer DD, Donoghue S, Cohen AF. de Boer A, et al. Thromb Haemost. 1992 Jul 6;68(1):24-9. Thromb Haemost. 1992. PMID: 1514168 Clinical Trial.

5

Diurnal rhythm in anticoagulant effect of heparin during a low dose constant rate infusion. A study in healthy volunteers.

Krulder JW, de Boer A, van den Besselaar AM, Cohen AF, Schoemaker HC, Briët E, Meinders AE. Krulder JW, et al. Among authors: de boer a. Thromb Haemost. 1992 Jul 6;68(1):30-2. Thromb Haemost. 1992. PMID: 1514169 Clinical Trial.

6

Interaction study between Org 10172, a low molecular weight heparinoid, and acetylsalicylic acid in healthy male volunteers.

de Boer A, Danhof M, Cohen AF, Magnani HN, Breimer DD. de Boer A, et al. Thromb Haemost. 1991 Aug 1;66(2):202-7. Thromb Haemost. 1991. PMID: 1722918 Clinical Trial.

7

Assessment of hepatic blood flow in healthy subjects by continuous infusion of indocyanine green.

Soons PA, De Boer A, Cohen AF, Breimer DD. Soons PA, et al. Among authors: de boer a. Br J Clin Pharmacol. 1991 Dec;32(6):697-704. Br J Clin Pharmacol. 1991. PMID: 1768562 Free PMC article. Clinical Trial.

8

Physical exercise induces enhancement of urokinase-type plasminogen activator (u-PA) levels in plasma.

Dooijewaard G, de Boer A, Turion PN, Cohen AF, Breimer DD, Kluft C. Dooijewaard G, et al. Among authors: de boer a. Thromb Haemost. 1991 Jan 23;65(1):82-6. Thromb Haemost. 1991. PMID: 1902597

9

Pharmacokinetics of saruplase, a recombinant unglycosylated human single-chain urokinase-type plasminogen activator and its effects on fibrinolytic and haemostatic parameters in healthy male subjects.

de Boer A, Kluft C, Gerloff J, Dooijewaard G, Günzler WA, Beier H, van der Meer FJ, Cohen AF. de Boer A, et al. Thromb Haemost. 1993 Aug 2;70(2):320-5. Thromb Haemost. 1993. PMID: 8236142 Clinical Trial.

10

Interaction study between nifedipine and recombinant tissue-type plasminogen activator in healthy subjects.

De Boer A, Kluft C, Kasper FJ, Kroon JM, Schoemaker HC, Breimer DD, Soons PA, Cohen AF. De Boer A, et al. Br J Clin Pharmacol. 1993 Aug;36(2):99-104. doi: 10.1111/j.1365-2125.1993.tb04203.x. Br J Clin Pharmacol. 1993. PMID: 8398589 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,398 results

Search Page

Filters